A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy

• Status: Terminated
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to compare the effects of TAS-102 with either amrubicin or topotecan (drugs used in Small Cell Lung Cancer) on lung cancer to find out the effects on survival, how much time may pass without disease progression, and the safety of TAS-102.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taiho Oncology, Inc.
• Collaborator: Taiho Pharmaceutical Co., Ltd.
• Treatments: Amrubicin; Topotecan; Trifluridine

Criteria

Inclusion Criteria:

1. Has provided written informed consent

2. Is ≥18 years of age for patients enrolled in Europe; or ≥20 years of age for patients enrolled in Japan

3. Has definitive histologically or cytologically confirmed SCLC (limited or extensive disease)

4. Has progressed or had recurrence within 30 days prior to randomization

5. Has at least one measurable lesion, as defined by RECIST criteria version 1.1

6. ECOG performance status of 0, 1, or 2

7. Is able to take medications orally

8. Has adequate organ function (bone marrow, kidney and liver)

9. Women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control.

Exclusion Criteria:

1. Has cerebral metastases (unless metastases have been treated and controlled, metastases have been stable for at least 2-months post-intervention, and patient is not receiving corticosteroid treatment)

2. Certain serious illnesses or medical condition(s)

3. Has had certain other recent treatment e.g. major surgery, anticancer therapy, extended field radiation, received investigational agent, within the specified time frames prior to study drug administration

4. Has received TAS-102

5. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any prior therapies

6. Is a pregnant or lactating female